Skip to main content
Caplight Logo









Tetraneuron

Tetraneuron

Private
MadridHealthcare & Life Scienceshttps://tetraneuron.com/en/

Last Round

VC Round

Dec 9, 2025

Total Funding Raised

$5.31M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Tetraneuron is a biotechnology company that develops AAV-based gene therapies to treat Alzheimer's disease and other neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyneurodegenerative diseaseAlzheimer's treatmentAAV9biotechdrug discoveryprecision medicinebiotech licensingneuronal homeostasisE2F4clinical stage biotechbiotech startuptherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tetraneuron Comparables

Compare Tetraneuron with similar companies based on industry and business-model similarity.

Tetraneuron comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LEXEO Therapeutics
77%
VectorY Therapeutics
74%
AviadoBio
74%

Tetraneuron Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 9, 2025
SeedDec 27, 2022

Key People

Founding team and executive leadership

Angel Lucio

Chief Executive Officer, Board Member and Seed Investor

Executive Team

Tetraneuron Investors

Notable investors and investment history

Tetraneuron investors
InvestorRounds
GIMIC VenturesVC Round
Johnson & Johnson Innovation - JLABSSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 162% MoM, reaching 3.4K.

  • Aug 16, 2026

    Grew 25% QoQ, from 16 to 20 employees.

Tetraneuron Filings

Explore SEC and related filing metadata, where available.

Tetraneuron filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Tetraneuron's valuation, stock price, and market status.

Is Tetraneuron a public or private company?

Tetraneuron is a private company.

What is the current stock price of Tetraneuron?

Tetraneuron is a private company with no public stock price. No recent secondary market data is available.

How much is Tetraneuron worth (valuation)?

Valuation information for Tetraneuron is not publicly available.

Can I buy Tetraneuron stock?

Tetraneuron shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Tetraneuron's last funding round?

Tetraneuron's most recent funding round was VC Round on December 9, 2025.

Who are the main investors in Tetraneuron?

Key investors in Tetraneuron include GIMIC Ventures.

Will Tetraneuron IPO soon?

No public IPO plans have been announced for Tetraneuron.

How can I track Tetraneuron secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tetraneuron's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMadrid
Employee Range16
Year Founded2012
Last FundingDec 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?